NEW YORK, Sept. 24 – The Genetics Company and Discovery Partners have partnered to identify potential drug targets for colon cancer, the companies said on Monday.

Discovery Partners, of San Diego, will screen thousands of chemical compounds for their ability to inhibit a protein that The Genetics Company has in previous studies linked to colon cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.